Shares of Fibrocell Science Inc (FCSC) stock are up more than 57% Monday following an announcement from the company that it will be collaborating with Castle Creek Pharmaceuticals to develop and commercialize FCX-007 gene therapy.
FCSC stock jumped as high as $3.24, which is 82% higher than Friday’s closing price of $1.78. The average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives FCSC stock a score of 86 out of a possible 100.
That score is chiefly influenced by a fundamental score of 90. In addition to the average rating from Wall Street analysts, FCSC stock has a mean target price of $16.00. This means analysts expect the stock to rise 471.43% over the next 12 months. FCSC’s score also includes a long-term technical score of 87. The short-term technical score for FCSC is 79.
What’s Happening with FCSC Stock Today
Fibrocell Science Inc (FCSC) stock is higher by 57.26% while the S&P 500 is down -0.15% as of 10:36 AM on Monday, Apr 15. FCSC has risen $1.02 from the previous closing price of $1.78 on volume of 20,622,521 shares. Over the past year the S&P 500 is higher by 8.41% while FCSC is down -12.50%. FCSC lost -$1.45 per share in the over the last 12 months.